Context

MedinCell is a clinical-stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients that are already known and marketed.

BEPO® technology makes it possible to control the delivery of a drug at the optimal therapeutic level through the subcutaneous or local injection of a fully bioresorbable deposit.

MedinCell will have two major milestones in H2 2020 from two strong partnerships: Phase 3 interim results with Teva (schizophrenia) and the start of Phase 3 with AiC (pain).

This capital raise will be used to finance formulation research activities and preclinical and clinical phases in pain, anaesthesia and Covid-19 (Ivermectin), and accelerate the development of its technology platform to other applications including health and organ transplantation).

About MedinCell

MedinCell is a clinical-stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, both through improved compliance with medical prescriptions and by significantly reducing the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months, starting from the subcutaneous or local injection of a simple deposit of a few millimeters that is fully bioresorbable. Based in Montpellier, France, MedinCell currently employs more than 130 people from over 25 different nationalities.

Discover MedinCell

Hervé Ronin

Investment Banking

Pierre Kiecolt-Wahl

Equity Capital Markets

Cosme Rosellini

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center